{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:01:31Z","timestamp":1762542091291},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Vaccines and Diagnostics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.vaccine.2012.01.062","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T17:38:37Z","timestamp":1337189917000},"page":"B18-B25","source":"Crossref","is-referenced-by-count":27,"special_numbering":"S2","title":["Meningococcal vaccine development \u2013 from glycoconjugates against MenACWY to proteins against MenB \u2013 potential for broad protection against meningococcal disease"],"prefix":"10.1016","volume":"30","author":[{"given":"Peter M.","family":"Dull","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. David","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2012.01.062_bib0005","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1369-5274(00)00119-3","article-title":"Reverse vaccinology","volume":"3","author":"Rappuoli","year":"2000","journal-title":"Curr Opin Microbiol"},{"issue":"45","key":"10.1016\/j.vaccine.2012.01.062_bib0010","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9580","key":"10.1016\/j.vaccine.2012.01.062_bib0015","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"issue":"RR-7","key":"10.1016\/j.vaccine.2012.01.062_bib0020","first-page":"1","article-title":"Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR Recomm Rep"},{"issue":"86","key":"10.1016\/j.vaccine.2012.01.062_bib0025","first-page":"521","article-title":"Meningococcal vaccines: WHO position paper","volume":"47","author":"SAGE","year":"2011","journal-title":"Wkly Epidemiol Rec (WER)"},{"issue":"41","key":"10.1016\/j.vaccine.2012.01.062_bib0030","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1016\/j.vaccine.2009.07.036","article-title":"Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages","volume":"27","author":"Broker","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2012.01.062_bib0035","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/01.inf.0000259996.95965.ef","article-title":"Use of meningococcal vaccines in the United States","volume":"26","author":"Bilukha","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2012.01.062_bib0040","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/jama.279.6.435","article-title":"Efficacy of meningococcal vaccine and barriers to vaccination","volume":"279","author":"Rosenstein","year":"1998","journal-title":"JAMA"},{"issue":"53","key":"10.1016\/j.vaccine.2012.01.062_bib0045","article-title":"Recommended adult immunization schedule\u2014United States","volume":"57","author":"CDC. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"July","key":"10.1016\/j.vaccine.2012.01.062_bib0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0140-6736(85)90224-7","article-title":"Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine","volume":"2","author":"Reingold","year":"1985","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2012.01.062_bib0055","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1086\/515346","article-title":"Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination","volume":"178","author":"Granoff","year":"1998","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2012.01.062_bib0060","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.062_bib0065","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1086\/315284","article-title":"Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine","volume":"181","author":"Richmond","year":"2000","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.062_bib0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tmaid.2009.12.001","article-title":"Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine","volume":"8","author":"Broker","year":"2010","journal-title":"Travel Med Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2012.01.062_bib0075","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/jama.280.19.1685","article-title":"Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial","volume":"280","author":"MacDonald","year":"1998","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2012.01.062_bib0080","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2012.01.062_bib0085","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.inf.0000126297.28952.f8","article-title":"Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants","volume":"23","author":"Rennels","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2012.01.062_bib0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","article-title":"Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications","volume":"39","author":"Br\u00f6ker","year":"2011","journal-title":"Biologicals"},{"issue":"10","key":"10.1016\/j.vaccine.2012.01.062_bib0095","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/nar\/12.10.4063","article-title":"The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197","volume":"12","author":"Giannini","year":"1984","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"10.1016\/j.vaccine.2012.01.062_bib0100","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.vaccine.2009.02.022","article-title":"Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae in Chilean infants","volume":"27","author":"Lagos","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2012.01.062_bib0105","first-page":"243","article-title":"Simultaneous administration of meningococcal C conjugate vaccine and diphtheria\u2013tetanus\u2013acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study","volume":"25","author":"Halperin","year":"2002","journal-title":"Clin Invest Med"},{"issue":"6","key":"10.1016\/j.vaccine.2012.01.062_bib0110","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.vaccine.2004.06.052","article-title":"Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines","volume":"23","author":"Huebner","year":"2004","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2012.01.062_bib0115","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1001\/jama.283.21.2795","article-title":"Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial","volume":"283","author":"MacLennan","year":"2000","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.vaccine.2012.01.062_bib0120","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.vaccine.2004.10.021","article-title":"Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135","volume":"23","author":"Bardotti","year":"2005","journal-title":"Vaccine"},{"issue":"9-10","key":"10.1016\/j.vaccine.2012.01.062_bib0125","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0264-410X(98)00348-X","article-title":"Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines","volume":"17","author":"Costantino","year":"1999","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2012.01.062_bib0130","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1128\/IAI.60.10.4009-4014.1992","article-title":"Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine","volume":"60","author":"Paoletti","year":"1992","journal-title":"Infect Immun"},{"issue":"18","key":"10.1016\/j.vaccine.2012.01.062_bib0135","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2012.01.062_bib0140","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.062_bib0145","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","article-title":"A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents","volume":"28","author":"Jackson","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.062_bib0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.062_bib0155","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2012.01.062_bib0160","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2012.01.062_bib0165","series-title":"49th annual meeting of IDSA","article-title":"Persistence of bactericidal antibodies and boosting after vaccination with Menveo\u00ae in adolescents enrolled in phase II and III clinical studies","author":"Jackson","year":"2011"},{"issue":"3","key":"10.1016\/j.vaccine.2012.01.062_bib0170","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/INF.0b013e31818e037d","article-title":"Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants","volume":"28","author":"Perrett","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.062_bib0175","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/INF.0b013e31823dce5c","article-title":"Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants","volume":"31","author":"Klein","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.062_bib0180","first-page":"133","article-title":"Meningococcal group B vaccine trial in Norway 1981\u20131982. Preliminary report of results available November 1982","volume":"6","author":"Froholm","year":"1983","journal-title":"NIPH Ann"},{"issue":"8","key":"10.1016\/j.vaccine.2012.01.062_bib0185","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1128\/JCM.26.8.1543-1548.1988","article-title":"Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection","volume":"26","author":"Rosenqvist","year":"1988","journal-title":"J Clin Microbiol"},{"issue":"12","key":"10.1016\/j.vaccine.2012.01.062_bib0190","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne","year":"1987","journal-title":"J Immunol"},{"issue":"8346","key":"10.1016\/j.vaccine.2012.01.062_bib0195","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2012.01.062_bib0200","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/infdis\/171.6.1481","article-title":"Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides","volume":"171","author":"Hayrinen","year":"1995","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2012.01.062_bib0205","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"03","key":"10.1016\/j.vaccine.2012.01.062_bib0210","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines\u2014Advisory Committee on Immunization Practices (ACIP)","volume":"60","year":"2010","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2012.01.062_bib0215","series-title":"Surveillance of invasive bacterial diseases in Europe 2008\/2009","author":"European Centre for Disease Prevention and Control","year":"2011"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.062_bib0220","first-page":"125","article-title":"Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway","volume":"14","author":"Bjune","year":"1991","journal-title":"NIPH Ann"},{"issue":"14","key":"10.1016\/j.vaccine.2012.01.062_bib0225","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.vaccine.2005.12.059","article-title":"Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks","volume":"25","author":"Taha","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2012.01.062_bib0230","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1590\/S0074-02761999000400002","article-title":"The epidemiological impact of antimeningococcal B vaccination in Cuba","volume":"94","author":"Rodriguez","year":"1999","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"8827","key":"10.1016\/j.vaccine.2012.01.062_bib0235","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2012.01.062_bib0240","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2012.01.062_bib0245","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1086\/315833","article-title":"Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992\u20131998","volume":"182","author":"Sacchi","year":"2000","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2012.01.062_bib0250","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years","volume":"38","author":"Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"issue":"16","key":"10.1016\/j.vaccine.2012.01.062_bib0255","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.vaccine.2007.01.023","article-title":"Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand","volume":"25","author":"Oster","year":"2007","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2012.01.062_bib0260","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","article-title":"Review of meningococcal Group B vaccines","volume":"50","author":"Granoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2012.01.062_bib0265","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2010.12.039","article-title":"A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","volume":"29","author":"Keiser","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.062_bib0270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/CVI.00230-06","article-title":"Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7\u20132,4) meningococcal outer membrane vesicle vaccine in healthy adolescents","volume":"14","author":"Boutriau","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"15","key":"10.1016\/j.vaccine.2012.01.062_bib0275","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0264-410X(99)00423-5","article-title":"Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2\u20133 and 7\u20138 years of age","volume":"18","author":"de Kleijn","year":"2000","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2012.01.062_bib0280","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.vaccine.2006.09.025","article-title":"Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs","volume":"25","author":"van den Dobbelsteen","year":"2007","journal-title":"Vaccine"},{"issue":"5459","key":"10.1016\/j.vaccine.2012.01.062_bib0285","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2012.01.062_bib0290","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2012.01.062_bib0295","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","article-title":"Functional significance of factor H binding to Neisseria meningitidis","volume":"176","author":"Schneider","year":"2006","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2012.01.062_bib0300","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2012.01.062_bib0305","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2958.2004.04423.x","article-title":"Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells","volume":"55","author":"Capecchi","year":"2005","journal-title":"Mol Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2012.01.062_bib0310","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.4049\/jimmunol.179.6.3904","article-title":"IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A","volume":"179","author":"Mazzon","year":"2007","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2012.01.062_bib0315","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/CVI.00036-08","article-title":"Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B","volume":"15","author":"Plested","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2012.01.062_bib0320","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2366","article-title":"Molecular mechanisms of complement evasion: learning from staphylococci and meningococci","volume":"8","author":"Serruto","year":"2010","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2012.01.062_bib0325","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1086\/379375","article-title":"Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity","volume":"188","author":"Welsch","year":"2003","journal-title":"J Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2012.01.062_bib0330","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2012.01.062_bib0335","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without Outer Membrane Vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2012.01.062_bib0340","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2012.01.062_bib0345","series-title":"17th international pathogenic Neisseria conference (IPNC)","article-title":"Immunogenicity of an investigational multicomponent meningococcal serogroup B vaccine in healthy infants at 2, 4 and 6 months of age","author":"Vesikari","year":"2010"},{"key":"10.1016\/j.vaccine.2012.01.062_bib0350","series-title":"29th annual ESPID conference","article-title":"Booster dose at 12 months of an investigational meningococcal serogroup B vaccine (4CMenB) in toddlers previously primed at 2, 4, 6 months","author":"Vesikari","year":"2011"},{"issue":"3","key":"10.1016\/j.vaccine.2012.01.062_bib0355","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2012.01.062_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase IIb\/III randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2012.01.062_bib0365","unstructured":"Donnelly J, Medina D, Giuliani M, Boccadifuoco G, Stella M, Frosi G, et al. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci. Poster presented at the 11th annual meeting of the European Meningococcal Disease Society (EMGM); 2011."},{"key":"10.1016\/j.vaccine.2012.01.062_bib0370","unstructured":"Novartis A phase 2b\/3, multi-center, extension study of V72P10 to assess antibody persistence at eighteen months after the completion of the vaccination course in study V72P10. http:\/\/clinicaltrialsgov\/show\/NCT01148524."},{"key":"10.1016\/j.vaccine.2012.01.062_bib0375","unstructured":"Novartis A phase 3 observer blind randomized, multi-center, controlled study to evaluate the effect of Novartis Vaccine's meningococcal B recombinant and MenACWY conjugate vaccines on pharyngeal carriage of N. meningitidis in young adults. http:\/\/clinicaltrialsgov\/show\/NCT01214850."},{"key":"10.1016\/j.vaccine.2012.01.062_bib0380","unstructured":"Novartis A phase 3, open-label, multi-center, extension study of V72P13E1 to assess antibody persistence at one year after a fourth dose boost or two catch-up doses of Novartis meningococcal B recombinant vaccine administered starting at 12 months of age and to evaluate the response to a third dose boost or two catch-up doses starting at 24 months of age. http:\/\/clinicaltrialsgov\/show\/NCT01139021."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12001004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12001004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T20:00:32Z","timestamp":1687464032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12001004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":76,"alternative-id":["S0264410X12001004"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.01.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}